{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:51:27Z","timestamp":1761094287880,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA016086"],"award-info":[{"award-number":["CA016086"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Otsuka America Pharmaceuticals, Inc"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.bbmt.2015.07.016","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T12:40:14Z","timestamp":1437568814000},"page":"2129-2135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase I\/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients"],"prefix":"10.1016","volume":"21","author":[{"given":"Thomas C.","family":"Shea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Walko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunro","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Sheets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamakshi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Comeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Coghill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Armistead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Sarantopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Serody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.07.016_bib1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic stem cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.07.016_bib2","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2012.46.6193","article-title":"Significant improvements in survival after allogeneic stem cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors","volume":"31","author":"Hahn","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.016_bib3","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2015.07.016_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4252\/wjsc.v6.i2.69","article-title":"Allogeneic hematopoietic cell transplant for acute myeloid leukemia: current state in 2013 and future directions","volume":"6","author":"Kanate","year":"2014","journal-title":"World J Stem Cells"},{"key":"10.1016\/j.bbmt.2015.07.016_bib5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2010.32.5001","article-title":"Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?","volume":"29","author":"Horan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.016_bib6","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcomes in patients with myelodysplastic syndrome after hematopoietic stem cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.016_bib7","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringden","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.016_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.leu.2404010","article-title":"Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis","volume":"20","author":"Scott","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.07.016_bib9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.016_bib10","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/blood-2007-06-096966","article-title":"Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences","volume":"110","author":"Sorror","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.016_bib11","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.016_bib12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihood for hematopoietic stem cell grafts in the U.S.","volume":"371","author":"Gragert","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.07.016_bib13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.beha.2011.05.002","article-title":"Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need","volume":"24","author":"Shimoni","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2015.07.016_bib14","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2010.28.6856","article-title":"Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian Trial AMLHD98A","volume":"28","author":"Schlenk","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.016_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.016_bib16","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2004-05-1947","article-title":"Comparative outcome of non-myeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age","volume":"105","author":"Alyea","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.016_bib17","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood-2013-07-514448","article-title":"Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI","volume":"122","author":"Copelan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.016_bib18","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","article-title":"Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation","volume":"122","author":"Bredeson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.016_bib19","first-page":"5994","article-title":"Influence of schedule on alkylating agent cytotoxicity in\u00a0vitro and in\u00a0vivo","volume":"49","author":"Teicher","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2015.07.016_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00686337","article-title":"A\u00a0phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients","volume":"29","author":"Eder","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2015.07.016_bib21","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.016_bib22","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.07.016_bib23","unstructured":"ASBMT RFI 2015 - Disease Classifications Corresponding to CIBMTR Classifications. Retrieved from: www.asbmt.org\/resource\/resmgr\/RFI\/RFI_2015_CIBMTR_Disease_Cl.pdf."},{"key":"10.1016\/j.bbmt.2015.07.016_bib24","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.1993.11.9.1729","article-title":"Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation","volume":"11","author":"Bearman","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.016_bib25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft vs. host disease in humans recipients of marrow from HLA-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2015.07.016_bib26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2015.07.016_bib27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/01.cad.0000127145.50172.51","article-title":"Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy","volume":"15","author":"Lindley","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bbmt.2015.07.016_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00694339","article-title":"Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation","volume":"25","author":"Grochow","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2015.07.016_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00007691-199810000-00017","article-title":"Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation","volume":"20","author":"Slattery","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bbmt.2015.07.016_bib30","first-page":"303","article-title":"Determination of busulfan in human plasma by gas chromatography with electron-capture detection","volume":"425","author":"Chen","year":"1988","journal-title":"J\u00a0Chromatogr"},{"key":"10.1016\/j.bbmt.2015.07.016_bib31","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.jspi.2006.07.009","article-title":"Cumulative cohort design for dose-finding","volume":"137","author":"Ivanova","year":"2007","journal-title":"J\u00a0Stat Plann Inference"},{"key":"10.1016\/j.bbmt.2015.07.016_bib32","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1541-0420.2005.00311.x","article-title":"Continuous toxicity monitoring in phase II trials in oncology","volume":"61","author":"Ivanova","year":"2005","journal-title":"Biometrics"},{"key":"10.1016\/j.bbmt.2015.07.016_bib33","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1182\/blood.V88.11.4383.4383","article-title":"Tacrolimus and minidose methotrexate for prevention of acute graft versus host disease after matched unrelated donor transplantation","volume":"88","author":"Przepiorka","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.016_bib34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":"Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.016_bib35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-200039020-00005","article-title":"Plasma concentration monitoring of busulfan: does it improve clinical outcome?","volume":"39","author":"McCune","year":"2000","journal-title":"Clin Pharmacokinet"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115004723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115004723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:53:43Z","timestamp":1761058423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115004723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1083879115004723"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.016","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I\/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}